This page is intended for US healthcare providers only.
This page is intended for US healthcare providers only.
HER2 PLAYS A CENTRAL ROLE IN MULTIPLE TUMOR TYPES1-3
HER2 signaling is a driver of tumor cell proliferation and survival.1,2
The HER2/HER3 heterodimer delivers the most potent signal for proliferation in tumor cells that overexpress HER2.2-4
HER2 targeting is an opportunity2,3
HER2 overexpression and/or amplification is an oncogenic driver in multiple tumor types, as well as a potential therapeutic target.
HER2 positivity across select cancers5-8
Discover the importance of testing for HER2 in mCRC.
Join our list of labs that test for HER2 in mCRC.
HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.
References: 1. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97(4):453-457. doi:10.1038/sj.bjc.6603910 2. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-275. doi:10.1016/j.jconrel.2010.04.009 3. Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108-1119. doi:10.1093/annonc/mdy100 4. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996;15(10):2452-2467. 5. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X 6. Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594-604. doi:10.1200/OP.21.00172 7. Kang A, Bloudek L, Mordi U, et al. Systematic literature review of HER2 amplification/overexpression in colorectal cancer. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 18-21, 2021; Denver, CO. 8. Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precis Oncol. 2020;4:411-425. doi:10.1200/PO.19.00333
Seagen and 
are US registered trademarks of Seagen Inc.
© 2024 Seagen Inc., Bothell, WA 98021.
All rights reserved. US-DIS-23-315-MT